NCT04220203 2025-06-26
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Seagen Inc.
Approved for marketing
Clinical Trials
3 trialsNCT02354612 2021-02-15
Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial
Tracon Pharmaceuticals Inc.
No longer available
NCT00338247 2016-04-06
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Novartis
Approved for marketing